Back to Search Start Over

Racial Health Disparity and COVID-19

Authors :
Benjamin Duhart
Sunitha Kodidela
Alina Cernasev
John J. Bissler
Udai P Singh
Asit Kumar
Anantha Nookala
Prashant Kumar
Santosh Kumar
Source :
Journal of Neuroimmune Pharmacology
Publication Year :
2021
Publisher :
Springer Science and Business Media LLC, 2021.

Abstract

The infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and resultant coronavirus diseases-19 (COVID-19) disproportionally affects minorities, especially African Americans (AA) compared to the Caucasian population. The AA population is disproportionally affected by COVID-19, in part, because they have high prevalence of underlying conditions such as obesity, diabetes, and hypertension, which are known to exacerbate not only kidney diseases, but also COVID-19. Further, a decreased adherence to COVID-19 guidelines among tobacco smokers could result in increased infection, inflammation, reduced immune response, and lungs damage, leading to more severe form of COVID-19. As a result of high prevalence of underlying conditions that cause kidney diseases in the AA population coupled with tobacco smoking make the AA population vulnerable to severe form of both COVID-19 and kidney diseases. In this review, we describe how tobacco smoking interact with SARS-CoV-2 and exacerbates SARS-CoV-2-induced kidney diseases including renal failure, especially in the AA population. We also explore the role of extracellular vesicles (EVs) in COVID-19 patients who smoke tobacco. EVs, which play important role in tobacco-mediated pathogenesis in infectious diseases, have also shown to be important in COVID-19 pathogenesis and organ injuries including kidney. Further, we explore the potential role of EVs in biomarker discovery and therapeutics, which may help to develop early diagnosis and treatment of tobacco-induced renal injury in COVID-19 patients, respectively. Graphical Abstract

Details

ISSN :
15571904 and 15571890
Volume :
16
Database :
OpenAIRE
Journal :
Journal of Neuroimmune Pharmacology
Accession number :
edsair.doi.dedup.....871e5035b11ff57e69722ab706bd28e2
Full Text :
https://doi.org/10.1007/s11481-021-10014-7